BioWorld Asia

Dec. 14, 2005

BioAlliance Pharma Completes Initial Public Offering For EUR30M

PARIS - BioAlliance Pharma SA completed its initial public offering on Eurolist Compartment C of the Euronext stock exchange in Paris, raising gross proceeds of some €30 million (US$35.9 million). (BioWorld International) Read More

Domantis' Valuation Higher For £17M Third Financing

Dutch Team Finds Aspects Of Cell Cycle Checkpoints

Zealand Pharma Learning Lessons From Pulled IPO

Group Of GMO Crop Raiders Acquitted By French Court

Cellartis Brings In EUR 8M For Embryonic Stem Cell Work

Alizyme Reports Positive Data For Cetilistat, Plans Phase III

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...

Photo of two people shaking hands near lab equipment

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

BioWorld

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...